Physician profile
Norman P Ayers
NPI 1265426498
$5,673.47
in general payments reported to CMS, 2019-2025
32 companies · $1,082 in 2025
The $1,082 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $1,440 · 2021: $518 · 2022: $1,147 · 2023: $596 · 2024: $338 · 2025: $1,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,015.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $864.64 | 2020-2022 | |
| Medtronic, INC. | $768.81 | 2021-2025 | Micra, Aurora Ev-Icd Mri Surescan, Symplicity G3 |
| Janssen Pharmaceuticals, INC | $602.62 | 2019-2023 | Xarelto |
| Abiomed | $357.87 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $349.94 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $265.33 | 2019-2021 | |
| Novo Nordisk INC | $228.31 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $210.71 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip |
| Actelion Pharmaceuticals US, INC. | $196.34 | 2019-2023 | Opsumit |
| E.R. Squibb & Sons, L.L.C. | $183.27 | 2020-2025 | Eliquis, Camzyos |
| Philips North America LLC | $176.09 | 2022-2025 | (Ck4) Mcot, Ecc Solutions |
| Medtronic Vascular, INC. | $171.82 | 2019-2020 | |
| Amgen INC. | $157.84 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $155.11 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $149.81 | 2023-2025 | Verquvo, Winrevair |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $131.54 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.60 | 2019-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $98.64 | 2019-2025 | Lifevest |
| Amarin Pharma, INC. | $97.70 | 2019-2021 | |
| Kestra Medical Technology Services, INC. | $87.30 | 2024-2025 | Assure Wcd |
| Esperion Therapeutics, INC. | $68.61 | 2020-2025 | Nexletol |
| W. L. Gore & Associates, INC. | $50.77 | 2023 | Gore Viabahn Vbx Balloon Expandable Endo |
| Cordis US Corp. | $36.32 | 2025 | Mynx Control Venous |
| Glaxosmithkline, LLC. | $31.77 | 2025 | Shingrix |
| Lundbeck LLC | $21.44 | 2019 | |
| Alnylam Pharmaceuticals INC. | $18.52 | 2023 | Onpattro |
| Stryker Corporation | $17.81 | 2025 | Triever20 |
| Lilly USA, LLC | $17.23 | 2025 | Mounjaro, Zepbound |
| Boston Scientific Corporation | $14.55 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $14.10 | 2024 | Arcalyst |
| Irhythm Technologies, INC. | $12.69 | 2019 | |
| Edwards Lifesciences Corporation | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Ayers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.